Healthcare Industry News:  Accuray 

Devices Oncology

 News Release - September 17, 2008

Accuray Launches New Configuration for CyberKnife System to Offer Hospitals Installation Flexibility

New Footprint Enables Hospitals to Save Construction Costs and Speed Deployment Time by Placing CyberKnife System in Existing Vault

SUNNYVALE, Calif., Sept. 17 (HSMN NewsFeed) -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that it is offering a new layout for the CyberKnife® Robotic Radiosurgery System treatment vault which will enable installation of the System into most existing conventional gantry LINAC vaults. With this new, smaller footprint, hospitals will be able to save hundreds of thousands of dollars or more on construction and shielding costs, and begin treating patients more quickly.

"Many of our potential customers have expressed interest in a CyberKnife System to replace an aging gantry LINAC. However, space constraints in existing facilities or the inability to build a new facility to house the CyberKnife System have impacted their final decision," said Eric P. Lindquist, senior vice president and chief marketing officer at Accuray. "Taking advantage of existing treatment room design and shielding, the new layout should enable an accelerated go-live schedule, allowing sites to begin treating patients within a significantly shorter period of time."

While nearly identical feature-wise to the standard CyberKnife vault layout, the gantry LINAC vault layout reduces both treatment vault and equipment room footprints, giving customers more flexibility in where they can place a CyberKnife System. Installation of the CyberKnife System in a gantry LINAC vault is enabled with minimal-to-no additional shielding and the redesign of treatment beams to avoid secondary shielding walls.

With nearly identical capabilities to that of the CyberKnife System in a standard vault layout, the gantry LINAC vault layout requires 34 percent less vault space. With only a limited reduction in robotic maneuverability, the vast majority of functionality is retained and is compatible with nearly all CyberKnife System product options.

Accuray will highlight its new vault layout at the company's booth #1701 during the 50th American Society for Therapeutic Radiology & Oncology (ASTRO) Annual Meeting September 21-25, 2008 in Boston.

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 140 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.Accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2008 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.


Source: Accuray

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.